期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
FOXA1 in prostate cancer 被引量:3
1
作者 hui-yu dong Lei Ding +3 位作者 Tian-Ren Zhou Tao Yan Jie Li Chao Liang 《Asian Journal of Andrology》 SCIE CAS CSCD 2023年第3期287-295,共9页
Most prostate cancers initially respond to androgen deprivation therapy(ADT).With the long-term application of ADT,localized prostate cancer will progress to castration-resistant prostate cancer(CRPC),metastatic CRPC(... Most prostate cancers initially respond to androgen deprivation therapy(ADT).With the long-term application of ADT,localized prostate cancer will progress to castration-resistant prostate cancer(CRPC),metastatic CRPC(mCRPC),and neuroendocrine prostate cancer(NEPC),and the transcriptional network shifted.Forkhead box protein A1(FOXA1)may play a key role in this process through multiple mechanisms.To better understand the role of FOXA1 in prostate cancer,we review the interplay among FOXA1-targeted genes,modulators of FOXA1,and FOXA1 with a particular emphasis on androgen receptor(AR)function.Furthermore,we discuss the distinct role of FOXA1 mutations in prostate cancer and clinical significance of FOXA1.We summarize possible regulation pathways of FOXA1 in different stages of prostate cancer.We focus on links between FOXA1 and AR,which may play different roles in various types of prostate cancer.Finally,we discuss FOXA1 mutation and its clinical significance in prostate cancer.FOXA1 regulates the development of prostate cancer through various pathways,and it could be a biomarker for mCRPC and NEPC.Future efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate cancer.We believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer. 展开更多
关键词 androgen receptor forkhead box protein A1 MUTATION prostate cancer
原文传递
Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway
2
作者 hui-yu dong Pan Zang +6 位作者 Mei-Ling Bao Tian-Ren Zhou Chen-Bo Ni Lei Ding Xu-Song Zhao Jie Li Chao Liang 《Asian Journal of Andrology》 SCIE CAS CSCD 2023年第6期687-694,共8页
Recent studies revealed the relationship among homologous recombination repair(HRR),androgen receptor(AR),and poly(adenosine diphosphate-ribose)polymerase(PARP);however,the synergy between anti-androgen enzalutamide(E... Recent studies revealed the relationship among homologous recombination repair(HRR),androgen receptor(AR),and poly(adenosine diphosphate-ribose)polymerase(PARP);however,the synergy between anti-androgen enzalutamide(ENZ)and PARP inhibitor olaparib(OLA)remains unclear.Here,we showed that the synergistic effect of ENZ and OLA significantly reduced proliferation and induced apoptosis in AR-positive prostate cancer cell lines.Next-generation sequencing followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed the significant effects of ENZ plus OLA on nonhomologous end joining(NHEJ)and apoptosis pathways.ENZ combined with OLA synergistically inhibited the NHEJ pathway by repressing DNA-dependent protein kinase catalytic subunit(DNA-PKcs)and X-ray repair cross complementing 4(XRCC4).Moreover,our data showed that ENZ could enhance the response of prostate cancer cells to the combination therapy by reversing the anti-apoptotic effect of OLA through the downregulation of anti-apoptotic gene insulin-like growth factor 1 receptor(IGF1R)and the upregulation of pro-apoptotic gene death-associated protein kinase 1(DAPK1).Collectively,our results suggested that ENZ combined with OLA can promote prostate cancer cell apoptosis by multiple pathways other than inducing HRR defects,providing evidence for the combined use of ENZ and OLA in prostate cancer regardless of HRR gene mutation status. 展开更多
关键词 APOPTOSIS enzalutamide nonhomologous end joining OLAPARIB prostate cancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部